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Abstract: Telbivudine was recently approved for the treatment of chronic hepatitis B. Phase III 
studies indicated its antiviral potency with 6- to 6.5-log copies/mL reductions in hepatitis B DNA 
levels at year 1, comparable to other potent agents such as entecavir or tenofovir. Genotypic 
resistance rates, however, reached 25% at year 2 in hepatitis B e-antigen positive subjects and 
11% in hepatitis B e-antigen negative subjects, preventing it from becoming a preferred first-line 
drug for hepatitis B. Furthermore, its signature resistance mutation (a change from methionine to 
isoleucine at position 204 in the reverse transcriptase domain of the hepatitis B polymerase) also 
confers cross-resistance to entecavir, lamivudine, and emtricitabine. Telbivudine is well tolerated, 
with elevations in creatine phosphokinase being the most common abnormality observed in 
clinical trials. Most often, elevations were asymptomatic. Future research in hepatitis B will focus 
on the best ways to use existing therapies, including telbivudine, sequentially or in combination 
in order to maximize viral suppression and minimize the development of antiviral resistance.
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Chronic hepatitis B affects nearly 350 million people worldwide, with prevalence 
varying geographically, from 8% in areas of endemicity such as Asia and Sub-Saharan 
Africa to 1% in Western countries.1 It is the leading cause of hepatocellular cancer,2 
present in 53% of cases. Chronic infection with hepatitis B can also lead to cirrhosis 
and its complications.
Over the past five years, the armamentarium of oral antiviral therapies against 
hepatitis B has grown from one nucleoside analogue (lamivudine) to three nucleoside 
analogues and two nucleotide analogues available in 2009. These oral agents joined the 
immunomodulatory drug interferon-alfa (along with its pegylated form) as treatment 
options for chronic hepatitis B.
One of the most recent hepatitis B drugs to become available is the L-nucleoside 
telbivudine, which was approved by the US Food and Drug Administration in October 
2006, and in the European Union and China in 2007. As the options for hepatitis B 
therapy grow, it becomes important to consider the relative potencies and resistance 
profiles of each available agent to maximize long-term viral suppression and prevent 
development of virologic breakthrough. In this article, the trials leading to telbivudine’s 
approval will be discussed, along with strategies for its potential incorporation into 
current treatment paradigms based on its comparative efficacy with other approved 
nucleoside analogues.Therapeutics and Clinical Risk Management 2009:5 790
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Structure and pharmacokinetics
Telbivudine (β-L-2′-deoxythymidine) is a β-L-nucleoside 
analogue of thymidine that impairs hepatitis B virus (HBV) 
DNA replication by leading to chain termination. It differs 
from the natural nucleotide only with respect to the location 
of the sugar and base moieties, taking on an levorotatory 
configuration versus a dextrorotatory configuration as do the 
natural deoxynucleosides.3 Lamivudine and emtricitabine 
are also L-nucleosides. Telbivudine contains a hydroxyl 
group at the 3′ position of the β-L-2′-deoxyribose sugar 
which confers specificity to HBV polymerase.3 Preclinical 
studies have shown no activity of telbivudine against 
human immunodeficiency virus (HIV), herpes simplex 
virus, varicella zoster virus, Epstein–Barr virus, adenovirus 
type-1, influenza, measles, or other viruses. It also does not 
appear to have any activity against the human cellular DNA 
polymerase. Although in vitro data have supported a lack 
of HIV activity, further in vitro data is needed. Entecavir, 
another HBV nucleoside analogue, was also not found to 
have HIV activity in preclinical in vitro HBV models. Clinical 
experience, however, confirmed suppression of HIV RNA 
and induction of HIV resistance with use of entecavir as 
monotherapy in HIV/HBV-coinfected patients.4,5 Indeed, one 
case report suggests that telbivudine may have some activity 
against HIV.6 Clearly, more clinical data is needed.
Telbivudine is rapidly absorbed, reaching peak concen-
tration within 2.5 to 3 hours after dosing.7 Absorption is 
not affected by food intake, and therefore, it may be taken 
with or without a meal, with comparable maximum plasma 
concentration (Cmax), time to maximum concentration (Tmax) 
and area under the plasma concentration-time curve (AUC0-t).8 
Once taken up into the hepatocyte, it is efficiently phos-
phorylated into its active 5′-triphosphorylated form by host 
cellular kinases. The half-life of the activated drug is long 
(14 hours), making once-daily administration of a 600 mg 
dose appropriate. It is eliminated unchanged through passive 
diffusion into the urine, with a renal clearance similar to that 
of creatinine. Therefore, dosage adjustment is required in 
renal impairment,9 with extension of the dosing interval for 
creatinine clearance less than 50 mL/minute.10 For patients 
on hemodialysis, the dose is 600 mg every 96 hours (every 
four days), given after dialysis, as a four-hour dialysis session 
causes a 23% decrease in total exposure if the dosage is 
given prior to the session.9 Telbivudine is neither an inducer 
nor inhibitor of human CYP450 enzymes. No changes 
in its pharmacokinetics were observed in patients with 
mild, moderate or severe hepatic impairment so no dosage 
modifications are required in these patients.11
Clinical efficacy
Hepatitis B therapy cannot cure infection and has not been 
shown to improve mortality or development of hepatocellular 
carcinoma,12 although in theory reduction of viral repli-
cation and amelioration of hepatic inflammation should 
decrease the likelihood of progression to the complications 
of hepatitis B. The efficacy of hepatitis B therapies are there-
fore measured by such surrogate endpoints as HBV DNA 
suppression, normalization of biochemical markers (alanine 
aminotransferase [ALT], aspartate aminotransferase [AST]), 
loss of hepatitis B e antigen (HBeAg) and seroconversion 
to hepatitis B e antibody (anti-HBe), and loss of hepatitis B 
surface antigen (HBsAg). Because most antiviral therapies 
need to be given for prolonged periods of time, there is 
growing interest in development of drugs or drug strategies 
that have low rates of drug resistance when used for many 
years. More emphasis has been recently placed on an agent’s 
“genetic barrier to resistance” when deciding its place in 
treatment algorithms, as exemplified by the recommendation 
against using lamivudine as a first-line agent in antiviral-naïve 
patients due to high rates of resistance.13
The approval of telbivudine was based on several large, 
double-blind, multicenter, randomized studies comparing 
telbivudine to other approved hepatitis B agents. The largest 
of these was the phase III international GLOBE trial, 
which enrolled 1370 HBeAg-positive and HBeAg-negative 
antiviral-naïve subjects and randomized them to receive 
either 600 mg of telbivudine or 100 mg of lamivudine 
once daily.14 A second phase III trial (study 015), identical 
in design and intervention, enrolled 332 patients in China 
only.15 Telbivudine has also been compared to adefovir in 
randomized, open-label study in HBeAg-positive patients 
(study 018).16
In the GLOBE trial, the primary outcome was a 
“therapeutic response” which was defined as a decrease in 
the HBV DNA level to 5 log copies/mL along with either 
a loss of HBeAg or ALT normalization. Secondary outcomes 
were histologic response, change in HBV DNA levels, 
HBeAg loss, HBsAg loss, HBeAg seroconversion, HBsAg 
seroconversion, and normalization of ALT. The authors 
also looked for virologic breakthrough, defined as a 1 log 
copies/mL increase in HBV DNA over nadir. Treatment-
emergent resistance mutations were screened for in anyone 
with virologic breakthrough as well as those with detectable 
HBV DNA at prespecified timepoints. The Chinese trial used 
decrease in HBV DNA at one year as the primary endpoint. 
Secondary endpoints included the proportion of subjects with 
HBV DNA  5 log copies/mL and proportion undetectable Therapeutics and Clinical Risk Management 2009:5 791
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at one year, normalization of  ALT, HBeAg loss, HBeAg 
seroconversion and therapeutic response, as defined in the 
GLOBE trial.
The GLOBE study included 683 patients randomized to 
receive telbivudine (458 HBeAg-positive and 222 HBeAg-
negative) and 687 patients randomized to receive lamivudine 
(463 HBeAg-poistive and 224 HBeAg-negative). Results 
through year 2 are summarized in Table 1. In this study, 
telbivudine showed a more potent HBV DNA reduction at 
one year compared to lamivudine in both HBeAg-positive 
and HBeAg-negative patients, with an average drop 
of -6.45 log copies/mL drop in HBeAg-positive patients 
and -5.23 log copies/mL in HBeAg-negative patients 
in the telbivudine groups, nearly a full log over changes 
in the lamivudine groups. The mean time to HBV DNA 
negativity was also shorter with telbivudine, 34 weeks versus 
39 weeks with lamivudine in HBeAg-positive (P  0.001) 
and 20 weeks versus 26 weeks with lamivudine in HBeAg-
negative (P  0.001). The less dramatic virologic results 
seen in HBeAg-negative patients may reflect their lower 
HBV DNA levels at baseline (9.5 log copies/mL in HBeAg-
positive versus 7.4 to 7.7 log copies/mL in HBeAg-negative). 
Telbivudine also outperformed lamivudine for therapeutic 
response, with 75% to 85% of HBeAg-positive patients and 
Table 1 Results of the phase iii GLOBe trial comparing telbivudine 600 mg daily to lamivudine 100 mg daily in nucleoside-naïve hepatitis B 
e-antigen positive and e-antigen negative subjects13,18
HBeAg-positive subjects














Therapeutic response 75.3% 67.0% 0.005 63.3% 48.2% 0.001
Histologic Response 64.7% 56.3% 0.01
Mean change in HBv DNA 
(log copies/mL)
-6.45 -5.34 0.001
Undetectable HBv DNA 60% 40.4% 0.001 55.6% 38.5% 0.011
ALT normalization 77.2% 74.9% 0.42 69.5% 61.7% 0.05
HBeAg loss 25.7% 23.3% 0.40 35.2% 29.2% 0.056
HBeAg seroconversion 22.5% 21.5% 0.73 29.6% 24.7% 0.095
virologic response 25.7% 22.8% 0.32
viral breakthrough 5.9% 15.9% 0.001 28.8% 46.9% 0.001
viral resistance 5.0% 11.0% 0.001 25.1% 39.5% 0.001








P  Telbivudine  
600 mg/day  
(n = 222)
Lamivudine  
100 mg/day  
(n = 224)
P
Therapeutic response 75.2% 77.2% 0.62 77.5% 66.1% 0.007
Histologic response 66.6% 66.0% 0.90
Mean change in HBv DNA  
(log copies/mL)
-5.23 -4.40 0.001
Undetectable HBv DNA 88.3% 79.3% 0.001 82.0% 56.7% 0.001
ALT normalization 74.4% 79.3% 0.24 77.8% 70.1% 0.073
viral breakthrough 2.3% 12.5% 0.001 12.2% 31.7% 0.001
viral resistance 2.2% 10.7% 0.001 10.8% 25.9% 0.001
Primary treatment failure 0.4% 2.7% 0.06 0.5% 0.9% 0.567
Notes: Therapeutic response = suppression of HBv DNA to 5 log copies/mL + either loss of HBeAg OR ALT normalization.
Abbreviations: ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBv, hepatitis B virus.Therapeutics and Clinical Risk Management 2009:5 792
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63% to 71% of HBeAg-negative patients experiencing this 
endpoint. Primary treatment failure (failure of treatment to 
suppress HBV DNA to 5 log copies/mL) seems to be rare 
with telbivudine, occurring in 5% of study subjects in 
GLOBE and study 015.
After one year of telbivudine, the HBeAg loss rates 
and HBeAg seroconversion rates were no different from 
lamivudine in the GLOBE trial, with HBeAg loss rates of 
25.7% and 23.3% for telbivudine and lamivudine, respectively 
(P = 0.40) and 22.5% and 21.5% for HBeAg seroconversion 
(P = 0.73). By year 2, however, telbivudine gained a slight, 
though not statistically significant advantage, with HBeAg 
loss rates of 35% and HBeAg seroconversion rates of nearly 
30%. HBsAg loss and HBsAg seroconversion were low with 
both treatments, as they have been with other nucleoside 
analogues.
ALT normalization occurred commonly with telbivudine 
and lamivudine in both HBeAg-positive and HBeAg-negative 
subjects. Overall, 77% of HBeAg-positive subjects and 
75% of HBeAg-negative subjects had ALT normalization at 
year 1, and nearly 70% of HBeAg-positive subjects and 78% 
of HBeAg-negative subjects reached this endpoint at year 2. 
The lower proportion having normal ALT at year 2 among 
HBeAg-positive patients may reflect the higher rate of viral 
breakthrough and resistance seen in year two in this group 
(see later discussion). The favorable effect on ALT, a marker 
of inflammation, was also mirrored by improvements in 
histology on paired liver biopsies at baseline and one year, 
which were seen in 65% to 66% of the telbivudine-treated 
patients, significantly more than the proportion of HBeAg-
positive patients treated with lamivudine with a histological 
response (56%, P = 0.01).
The smaller study 015 completed in China, randomized 
147 HBeAg-positive and 20 HBeAg-negative patients to 
telbivudine and 143 HBeAg-positive and 22 HBeAg-negative 
patients to lamivudine. The results were strikingly similar to 
the results from the GLOBE study, indicating little ethnic 
variation in the efficacy of telbivudine.15,17 HBV DNA 
reduction was -6.3 log copies/mL in HBeAg-positive patients 
and -5.5 log copies/mL in HBeAg-negative patients, again 
a nearly 1 log increase over the changes seen in lamivudine-
treated patients at one year. ALT normalization at one year 
was seen in 87% of HBeAg-positive and 100% of HBeAg-
negative patients treated with telbivudine. Although HBeAg 
loss occurred more often with telbivudine than lamivudine at 
one year (31% vs 20%, P = 0.047), HBeAg seroconversion 
was not statistically significant (25% vs 18%, P = 0.14). Sixty-
seven percent of telbivudine-treated HBeAg-positive patients 
became undetectable by PCR assay at year 1, while therapeutic 
response was seen in 85% of telbivudine patients versus 
only 62% of lamivudine subjects (P  0.001). No patient 
experienced HBsAg loss or HBsAg seroconversion.
Participants in both the GLOBE and study 015 were 
offered participation in a phase IIIb extension study offering 
two years additional treatment with continued monitoring of 
treatment responses. Ninety-three HBeAg-positive patients 
with HBeAg seroconversion and HBV DNA  300 copies/mL 
met the criteria for entrance into the rollover protocol.18 
Of these 93 patients, 77% maintained HBeAg seroconversion 
and HBV DNA  300 at year 3. All had maintained HBeAg 
loss, but only 93% maintained HBeAg seroconversion. 
Among six patients who lost anti-HBe, six had low levels 
of HBV DNA (5 log copies/mL). Ninety-one percent 
of patients maintained normal ALT at year 3. Therefore, 
for those responding to telbivudine, the response appears 
durable. HBeAg-positive subjects in GLOBE were also 
offered the option of stopping study drug if HBeAg loss had 
been maintained for 24 weeks with an undetectable HBV 
DNA. Of the 38 telbivudine patients who elected to do so, 
82% sustained HBeAg loss through the last study visit after 
a median post-treatment follow up of 29.1 weeks.19
Telbivudine has also been compared to adefovir in 
one trial in HBeAg-positive patients.16 In this randomized, 
controlled, open-label study telbivudine 600 mg daily for 
52 weeks was compared to adefovir 10 mg daily for 52 weeks 
or 24 weeks of adefovir followed by 24 weeks of telbivudine, 
with approximately 45 patients randomized to each group. 
The investigators found no differences at week 52 between 
any of the groups with regard to reduction in HBV DNA, 
proportion of subjects with undetectable HBV DNA by 
PCR assay, biochemical response, HBeAg loss, or HBeAg 
seroconversion (Table 2). There was, however, a statistically 
significant difference between the amount of HBV DNA 
reduction at week 52 and the residual HBV DNA level at this 
time point in favor of telbivudine by almost 1 log copies/mL. 
There was also a much higher primary failure rate in both ade-
fovir groups (29% in the adefovir only group, 11% among the 
adefovir to telbivudine group, and 2% in the telbivudine only 
group) which was statistically significant. This is consistent 
with prior data confirming the suboptimal antiviral activity 
of adefovir against hepatitis B and its relative lack of potency 
compared to other available hepatitis B agents.20
Combination therapy
In the treatment of HIV, combination therapy with nucleoside 
analogues is standard care and well established as superior Therapeutics and Clinical Risk Management 2009:5 793
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to sequential monotherapy.21 In vitro pharmacologic data 
in HBV support additive antiviral effects by the Loewe 
additivity model and the Bliss independence model when 
adefovir and telbivudine were applied to transfected HepG2 
cells.22 These same models also demonstrated additive 
antiviral effects when telbivudine was combined with either 
entecavir or tenofovir in vitro.23
Similarly convincing clinical data in HBV are lacking, with 
de novo nucleoside (or nucleoside/nucleotide) combinations 
failing to show improved efficacy over monotherapy.24–26 
In these studies, rates of HBeAg loss, HBeAg seroconversion, 
magnitude of HBV DNA suppression and proportion 
undetectable at one year have not differed among subjects 
randomized to dual therapy versus monotherapy. Most 
studies have been too short to show a benefit on prevention 
of drug resistance, which is one of the primary benefits 
to combination therapy in HIV. Furthermore, many of the 
clinical combination therapy studies in HBV have studied less 
potent drugs (adefovir) or drugs with high rates of resistance 
(lamivudine) in combination and have not included newer, 
potent drugs with higher genetic barriers to resistance.
Telbivudine has been studied in combination with 
lamivudine for HBeAg-positive chronic hepatitis B.24 Subjects 
were randomized to receive lamivudine alone, telbivudine 
at one of two doses alone or lamivudine plus telbivudine at 
one of two doses together. The telbivudine groups were later 
pooled for analysis. At week 52, the lamivudine group (n = 19) 
had a -4.66 log copies/mL drop in HBV DNA compared to a 
greater than 6 log copies/mL drop in both the monotherapy 
(n = 44) and combination (n = 41) telbivudine groups. The 
proportion of subjects with undetectable HBV DNA at week 
52 was significantly less in the lamivudine group (32%) than 
in either of the telbivudine groups which were not signifi-
cantly different from one another (61% in the telbivudine 
monotherapy group and 49% in the combination therapy 
group). There were no differences among the three groups 
with regard to ALT normalization, HBeAg loss, HBeAg 
seroconversion, or therapeutic response. Virologic break-
through occurred in 3/19 (15.8%) of lamivudine patients, 
2/44 (4.5%) of telbivudine patients, and 5/41 (12.2%) of 
combination therapy patients. Two lamivudine breakthroughs 
had the rtM204I mutation and one had rtM204V + L180M. 
Both telbivudine breakthroughs carried the rtM204I mutation. 
In the combination group, three patients had rtM204I, one had 
M204V+L180M and one had wild-type HBV. As discussed 
later, telbivudine and lamivudine are now known to share the 
same pattern of resistance so it is unlikely that they would 
now be used together in combination therapy.
Safety
Because of its specificity for hepatitis B and selectivity for 
the viral polymerase rather than the host cellular polymerase, 
there are few adverse effects associated with the use of 
telbivudine. Preclinical27 and phase 1 and 2 studies7 showed 
no major toxicities associated with its use in humans. In the 
phase III GLOBE and study 015, there were no serious 
adverse events that led to drug discontinuation or death.14,15 
In both of these studies, elevations in the creatine phospho-
kinase (CPK) were seen more frequently and were higher 
than in those subjects receiving lamivudine. Grade 3/4 CPK 
elevations occurred in 12.9% of telbivudine subjects versus 
4.1% of lamivudine patients in the GLOBE trial (P  0.001) 
after a mean time of 56.9 weeks to first elevation. There 
were no cases of rhabdomyolysis, although one case was 
associated with a symptomatic myopathy, which was reported 
as a serious adverse event.19 In most cases, the elevations in 
CPK were not correlated with musculoskeletal symptoms, 
and were transient, resolving with the next laboratory check. 
Table 2 Telbivudine (LdT) 600 mg daily versus adefovir (ADv) 10 mg daily versus adefovir 10 mg for 24 weeks then telbivudine 
600 mg daily for 24 weeks in nucleoside naïve hepatitis B e-antigen-positive patients (week 52 results)15
  Telbivudine Adefovir Adefovir → telbivudine P (LdT vs ADV) P (switch vs ADV)
HBv DNA reduction  
(log copies/mL)
-6.56 -5.99 -6.44 0.11 0.18
Undetectable HBv DNA 60% 40% 54% 0.07 0.20
Mean HBv DNA  
(log copies/mL)
3.01 4.00 3.02 0.004 0.01
ALT normalization 79% 85% 85% 0.45 0.98
HBeAg loss 30% 21% 26% 0.25 0.53
HBeAg seroconversion 27% 18% 24% 0.34 0.51
Primary treatment failure 2% 29% 11% 0.008 0.042
Abbreviations: ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBv, hepatitis B virus.Therapeutics and Clinical Risk Management 2009:5 794
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Grade 3/4 elevations in CPK were also seen with more 
frequency in the telbivudine group in study 015 (8.4% versus 
3.0% in the lamivudine group) but this did not reach statistical 
significance (P = 0.06).15 The only other serious adverse event 
not related to muscle enzymes or myopathy associated with 
telbivudine was one instance of liver failure which occurred 
with an episode of virologic breakthrough that occurred with 
the development of telbivudine resistance in the GLOBE 
trial.19 Post-marketing reports have added additional case 
reports of myopathy and CPK elevations to the literature,28,29 
as well as case reports of neuralgia and numbness and cardiac 
arrhythmia.29 The mechanisms for myopathy and peripheral 
neuropathy are not clear. Other nucleoside analogues, such 
as fialuridine, have been associated with mitochondrial 
toxicity leading to distortions of cell energy metabolism with 
subsequent lactic acidosis, myopathy, peripheral neuropathy 
and hepatic steatosis through inhibition of the mitochondrial 
DNA polymerase gamma.30,31 Preclinical studies in ani-
mals did not demonstrate any mitochondrial toxicity with 
telbivudine27 and thus far, there is no clinical evidence that 
this is the mechanism underlying the observed myopathies 
in clinical trials. Animal studies of telbivudine showed 
axonopathic changes in the sciatic nerves and spinal cord of 
cynomolgus monkeys receiving the drug for nine months, 
but telbivudine’s role in pathogenesis was determined to be 
equivocal.27
Telbivudine resistance
Because hepatitis B cannot be eradicated,32 long-term suppres-
sion of viral replication remains the therapeutic goal, either 
by induction of HBeAg seroconversion via drug therapy or 
by long-term maintenance therapy with antivirals (usually the 
only choice in HBeAg-negative chronic hepatitis B). A few 
studies have reported sustained responses after discontinuation 
of antiviral therapy after two to three years of sustained viro-
logical suppression in HBeAg-negative disease,33,34 but clinical 
and virologic relapses are frequent with this approach.
The biggest hindrance to long-term virologic suppression 
of HBV DNA is the development of drug resistance. With 
lamivudine, the HBV drug with the lowest genetic barrier 
to resistance, rates of failure and genotypic resistance are 
17% after one year of therapy and increase to 70% after 
four years.35 In HIV-coinfected patients, lamivudine-resistant 
HBV develops even more quickly, with nearly 95% of 
patients resistant after four years of treatment.36,37 In contrast, 
the drug with highest genetic barrier to resistance (requiring 
three mutations in the reverse transcriptase gene) has a rate 
of only 1.2% after six years of therapy in nucleoside-naïve 
patients.38 Long-term data on tenofovir are not yet available. 
To date, no mutations conferring resistance to tenofovir 
have been conclusively identified, although clinical failures 
are well-described.39–42 Adefovir falls somewhere in the 
middle, with resistance rates of 0%, 3%, 11%, 18%, and 
29% in years 1 through 5, respectively.43
In the GLOBE trial, telbivudine breakthrough and 
genotypic resistance rates varied by the HBeAg status of the 
subjects. Among HBeAg-positive subjects, virologic break-
through at one year was about 6%, with genotypic resistance 
seen in 5%.14 The corresponding rates in HBeAg-negative 
subjects were 2.3% for virologic breakthrough and 2.2% for 
genotypic resistance. By year 2, 28.8% of HBeAg-positive 
subjects had breakthrough and 25% had resistance. Among 
HBeAg-negative subjects, the rates were less than half, with 
breakthrough in 12% and resistance in 10.8%. Rates were 
comparable at year 1 in the Chinese study (study 015).15 
Subjects experiencing virologic breakthrough in GLOBE 
were successfully salvaged with adefovir, either as add-on 
therapy or in substitution for telbivudine.44
Hepatitis B resistance is conferred by mutations in the 
reverse transcriptase domain of the HBV polymerase. For 
telbivudine, resistance is conferred by a single mutation 
at position rt204 that changes methionine to isoleucine 
(rtM204I).14 Secondary mutations rtL80I/V and L80I/V + 
L180M can accompany this signature mutation in approxi-
mately 2% and 0.3% of cases, respectively.14 This signature 
mutation, rtM204I, is also one of the signature mutations for 
lamivudine (the other being rtM204V).45 Therefore, patients 
failing telbivudine are unlikely to respond to lamivudine. 
There is in vitro data to suggest that telbivudine may retain 
activity against rtM204V single mutants, suggesting that 
this cross-resistance may not be bidirectional.46 Clinical data 
to support the use of telbivudine after lamivudine failure 
with rtM204V are lacking, and such a strategy cannot be 
recommended without more data.
In addition, the rtM204I mutation is a prerequisite for 
the development of entecavir resistance. Failure of entecavir 
is rare in nucleoside naïve patients because three mutations 
must develop for resistance to occur.47–49 In addition to a 
substitution at rt204 (either rtM204V or M204I), changes 
must also occur at two other positions (I169, T184, S202, 
or M250).50 This had led to much different long-term 
entecavir resistance rates in nucleoside-naïve patients 
(1.2% at six years)38 versus those with pre-existing lamivudine 
resistance, where the cumulative rate of entecavir virologic 
breakthrough at four years was 39.5%.51 Since lamivudine 
and telbivudine share the same signature mutation, it should Therapeutics and Clinical Risk Management 2009:5 795
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follow that telbivudine-experienced patients would also not 
respond as well to entecavir as nucleoside-naïve patients.
Adefovir and tenofovir do not share this same mutation 
pattern as telbivudine. Resistance to adefovir is conferred by 
a mutation at position rt236 from asparagine to threonine, 
which confers a 7- to 13-fold reduction in HBV susceptibility 
to the drug.52 A mutation from alanine to threonine at position 
rt181 is also associated with adefovir resistance, albeit at a 
lower level.53 No definitive tenofovir mutations have been 
described to date, although rtA194T has been identified in 
some clinical failures.40,54 Others have not confirmed these 
findings.55 None of these adefovir or tenofovir mutations 
have been associated with reduced response to telbivudine 
either clinically or in vitro,46,54 suggesting little or no cross-
resistance between it and these nucleotide analogues.
Incorporation of telbivudine 
into treatment algorithms
As the landscape of HBV treatment has become more 
complex, the choice of initial treatment has become increas-
ingly important in maximizing potency and minimizing 
antiviral resistance. When considering these factors, telbivu-
dine falls in the middle of the nucleos(-t)ide pack for both, 
as discussed above. Its place in the HBV armamentarium is 
therefore ill-defined.
Several sets of guidelines on the treatment of chronic 
hepatitis B have been published by professional societies.13,56–58 
While each are in general agreement about when HBV therapy 
is indicated, they each pose slightly different recommenda-
tions regarding the choice of initial therapy and the specific 
role of telbivudine in the sequencing of available antivirals. 
The American Association for the Study of Liver Disease 
(AASLD) Guidelines and the European Association for 
the Study of  the Liver (EASL) Guidelines both recommend 
entecavir or tenofovir as first-line agents when nucleos(-t)ide 
analogues are being chosen for therapy.13,58 A second US 
guideline (the US Treatment Algorithm, compiled by an 
expert panel of hepatologists) also endorses entecavir or 
tenofovir as first-line nucleoside analogues.56 In contrast, the 
Asian–Pacific consensus statement on the management of 
chronic hepatitis B for 2008 considers lamivudine, adefovir, 
entecavir, and telbivudine all to be first-line agents for 
hepatitis B (tenofovir has not yet become available there).57 
The first three guidelines base their recommendations on 
the relative potencies and high genetic barriers of resistance 
for entecavir and tenofovir which make them superior to 
the other options. With the high burden of disease in Asia 
and the Pacific Islands, the authors of the Asian-Pacific 
consensus statement acknowledge the need for clinicians to 
consider drug availability, affordability, and patient choice 
when making therapeutic decisions. Given the similar rates 
of HBeAg loss and seroconversion with the agents available 
there, they felt there was not enough evidence to support 
recommending one drug over another when all other factors 
were also considered. Regarding telbivudine specifically, 
the AASLD guidelines state that “telbivudine monotherapy 
has a limited role in the treatment of hepatitis B”. There are 
no specific situations in the AASLD guidelines in which 
telbivudine is considered a drug of choice. The EASL guide-
lines are similar, although they do recommend telbivudine as 
an option in the rare situation where HBV needs to be treated 
in the absence of HIV.
Whichever drug is chosen as first-line, the monitoring 
for development of resistance is paramount to ongoing care. 
HBV DNA levels and ALT levels should be measured every 
three to six months. It is typical to see a rise in HBV DNA 
prior to biochemical flare. When this occurs, assessment 
of adherence to therapy should be confirmed. If adherence 
is determined to be acceptable, drug resistance is the most 
likely cause of the rise in HBV DNA, and therapy should 
be modified immediately, to achieve the best outcomes and 
avoid flare of hepatitis. The choice of salvage therapy and 
whether to add on or switch depends on the drug used for 
initial therapy. The AASLD guidelines, EASL guidelines, 
and US treatment algorithm, which all recommend entecavir 
or tenofovir first-line, recommend a switch to or add on of the 
other if resistance occurs. If the initial therapy was something 
besides entecavir or tenofovir, the salvage drug becomes more 
complex. Add-on telbivudine would be an option for those 
failing adefovir or tenofovir. The Asian–Pacific consensus 
statement offers little guidance for those who develop 
resistance; recommendations are consistent with known 
cross-resistance patterns for the agents used.
The US treatment algorithm introduces another approach 
to HBV treatment based on viral kinetic responses on 
treatment, or the “HBV Roadmap Concept”. This concept 
grew, in part, from data in the GLOBE study of telbivudine 
that HBV DNA suppression at week 24 (or lack thereof) could 
predict HBeAg loss and seroconversion at week 104.59 In that 
study, among patients with HBV DNA  4 log copies/mL at 
week 24 of telbivudine, HBeAg seroconversion was 10% at 
week 104 compared to 86% in those with undetectable HBV 
DNA at week 24. Rates of resistance were also correlated with 
week 24 response, with 6% resistance at week 104 among 
subjects with undetectable HBV DNA at week 24 and 49% 
resistance rate in those with HBV DNA  4 log copies/mL.19 Therapeutics and Clinical Risk Management 2009:5 796
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The algorithm recommends an assessment of antiviral 
efficacy at week 24 for patients beginning HBV therapy. 
If the patient has experienced a complete response (HBV 
DNA negative by polymerase chain reaction), the same 
therapy can be continued with appropriate monitoring. 
If the virologic response is inadequate (2000 IU/mL, 
or 10,000 copies/mL), a more potent drug should be 
added, and monitoring continued every three months. If there 
has been a partial virologic response (HBV DNA  60 to 
2000 IU/mL or 300 to 10,000 copies/mL), the change 
depends on the initial drug used. For drugs with a low genetic 
barrier to resistance (lamivudine, telbivudine), a second drug 
with a different genetic mutation profile should be added. 
For drugs with a high genetic barrier to resistance (tenofovir, 
entecavir), the patient should continue to be monitored every 
three months with no drug added. For patients on a drug with 
suboptimal viral potency (adefovir, telbivudine), physicians 
should continue to monitor until 48 weeks and then add 
another more potent drug that is not cross-resistant if not 
fully suppressed.56
To date, there have been no specific studies of telbivudine 
in the setting of pre- or post-liver transplantation.
Summary and future directions
The last five years have emerged as a new era in the treatment 
of chronic hepatitis B. Advances in therapeutics and the 
approval of new drugs have been accompanied by a better 
understanding of natural history and pathogenesis, as well as 
better diagnostics. There are few new drugs for hepatitis B 
in the pipeline, with the agent farthest along in development, 
clevudine, halted for problems with muscle toxicity.60 There-
fore, future directions in hepatitis B therapy will focus on 
using the available drugs most effectively, either through 
logical sequential therapy or combinations of drugs to delay 
the development of drug resistance. In addition, methods of 
cost-efficiently determining resistance mutations will need to 
be developed and made commercially available as treatment 
failure becomes more complex. Results of genotypic testing 
can then be used to inform later therapeutic decisions.
Telbivudine remains a drug searching for its niche in the 
hepatitis B world. Although it has potent viral suppression, 
high resistance rates keep it from being a preferred agent. 
As an L-nucleoside, its signature mutation, rtM204I, 
confers full cross-resistance to lamivudine and partial cross-
resistance to entecavir. Cross-resistance to emtricitabine 
(currently being investigated for hepatitis B) is also predicted. 
Therefore, use as initial therapy not only causes the loss of 
itself as a treatment option, but also the loss of several other 
agents, including the most potent and durable option for 
hepatitis B, entecavir. Telbivudine’s role now is best defined 
as add-on therapy for the nucleotide analogues (adefovir or 
tenofovir) when a suboptimal or partial virologic response 
is observed at week 48 or when resistance develops to one 
of these agents. Other possibilities for use that should be 
investigated include prophylaxis before chemotherapy 
in hepatitis B carriers or as prophylaxis in liver transplant 
recipients of hepatitis B core antibody-positive livers. In both 
these scenarios, telbivudine offers an option with less chance 
of resistance than the currently used lamivudine, albeit at 
higher cost. Consequently, telbivudine will remain a “B” list 
drug in the “B” world.
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